DexCom Faces Class Action Lawsuit with December 29 Deadline for Lead Plaintiff
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 21 hour ago0mins
- Class Action Reminder: Rosen Law Firm alerts investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, that they must apply to be lead plaintiff by December 29, 2025, to participate in the class action and seek compensation.
- Legal Risks Unveiled: The lawsuit alleges that DexCom made unauthorized significant design changes to the G6 and G7 continuous glucose monitoring systems, resulting in decreased reliability and posing health risks to users, which may lead to increased regulatory scrutiny and legal liabilities.
- Investor Losses: As the true details emerged, investors suffered damages due to DexCom's misleading statements, highlighting the significant health risks and legal consequences that the company failed to disclose in its public statements.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and resource advantages in handling such cases.
DXCM.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 67.560
Low
63.00
Averages
85.75
High
112.00
Current: 67.560
Low
63.00
Averages
85.75
High
112.00
Citi
Buy
maintain
$75 -> $77
2025-12-11
New
Reason
Citi
Price Target
$75 -> $77
2025-12-11
New
maintain
Buy
Reason
Citi raised the firm's price target on DexCom to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an "upside 90-day catalyst watch" on DexCom. The firm sees the stock moving higher on the company's 2026 guidance in January.
Morgan Stanley
Patrick Wood
Equal Weight
to
Overweight
upgrade
$75
2025-12-02
Reason
Morgan Stanley
Patrick Wood
Price Target
$75
2025-12-02
upgrade
Equal Weight
to
Overweight
Reason
Morgan Stanley analyst Patrick Wood upgraded DexCom to Overweight from Equal Weight with a $75 price target.
Morgan Stanley
Morgan Stanley
Equal Weight -> Overweight
upgrade
$63 -> $75
2025-12-02
Reason
Morgan Stanley
Morgan Stanley
Price Target
$63 -> $75
2025-12-02
upgrade
Equal Weight -> Overweight
Reason
As previously reported, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, up from $63, citing signs that the company is already turning the corner from a number of operational challenges while valuation remains at trough levels. The firm expects this turn to become apparent in the full results due in January or February, adding that it believes the G7 15-day rollout's impact on margins in the year ahead is "underappreciated" and it expects the stock to re-rate as catalysts play out.
BofA
analyst
Buy
maintain
$10
2025-11-25
Reason
BofA
analyst
Price Target
$10
2025-11-25
maintain
Buy
Reason
After the Office of Inspector General report on Medicare payments for continuous glucose monitors and supplies came out, BofA noted that the report is just the OIG's recommendation to CMS and is not an update to the CMS proposal regarding competitive bidding from July. With that said, the firm views the OIG report positively for DexCom as it shows Class 2 supplies are priced fairly to in line with Medicare expectations, adds the analyst, who maintains a Buy rating and $10 price target on the shares.
See All Ratings
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What fiduciary duties are DexCom officers accused of breaching?
How do unauthorized design changes to G6 and G7 impact device reliability?
How might DexCom's stock price react to ongoing class action lawsuits?
What are the potential long-term effects of regulatory scrutiny on DexCom?